Creo Medical Group (LON:CREO) Stock Falls 1.8% – Should You Sell?

Creo Medical Group PLC (LON:CREO) fell 1.8% during mid-day trading on Friday. The company traded as low as GBX 11.05 and last traded at GBX 11.05. Approximately 175,788 shares were traded during trading, a decline of 78% from the average session volume of 787,611 shares. The stock had previously closed at GBX 11.25.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group reaffirmed a “house stock” rating and set a GBX 40 price objective on shares of Creo Medical Group in a research note on Thursday, July 23rd.

Creo Medical Group Price Performance

The stock has a fifty day simple moving average of GBX 11.86 and a two-hundred day simple moving average of GBX 12.66. The company has a market cap of £49.63 million, a PE ratio of -2.21 and a beta of 1.56. The company has a current ratio of 2.79, a quick ratio of 2.19 and a debt-to-equity ratio of 8.09.

Creo Medical Group (LON:CREO) last released its quarterly earnings data on Wednesday, September 30th. The company reported GBX (2) earnings per share (EPS) for the quarter. Creo Medical Group had a negative return on equity of 38.29% and a negative net margin of 268.57%. On average, equities analysts predict that Creo Medical Group PLC will post -10.08 EPS for the current fiscal year.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.